logo
Thiam delisting could rattle Côte d'Ivoire business confidence

Thiam delisting could rattle Côte d'Ivoire business confidence

Yahoo09-05-2025

The disqualification of Côte d'Ivoire's main opposition candidate from the race to become the country's next president could undermine the nation's reputation as a stable investment hub, his lawyer told Semafor.
A court ruling last month barred former Credit Suisse CEO Tidjane Thiam, leader of the Democratic Party of Ivory Coast (PDCI), from running in October's presidential election. He revoked his previous French citizenship in February, with the request approved the following month. But the court ruled that he didn't revoke his French citizenship early enough to qualify for this year's vote..
The decision 'sends a devastating signal,' Thiam's lawyer, Mathias Chichportich, told Semafor. Investors may struggle to trust a state that disregards its own laws, he argued, adding that political and legal uncertainty creates instability that may deter investment.
In a glowing April report, the International Monetary Fund said Côte d'Ivoire had emerged as an 'engine of growth and stability' in the eight-country West African Economic and Monetary Union of Francophone African countries. GDP growth in the country averaged 6.4% over the past decade, around 3 percentage points higher than the average for sub-Saharan Africa. Côte d'Ivoire also attracts nearly 30% of foreign direct investment in WAEMU — more than any other nation in the group — according to data from the UN's trade and development body.
Analysts warn that Thiam's disqualification, amid uncertainty over whether 83-year-old President Alassane Ouattara will seek a fourth term, could lead to damaging instability in Francophone West Africa's biggest economy. 'Thiam's disqualification sends a negative signal for a country like Côte d'Ivoire, which otherwise enjoys strong governance indicators in the region,' said Aroni Chaudhuri, Africa economist at the French credit insurer Coface.
Thiam's exclusion stems from a legal complaint filed by private citizens citing a rarely used clause in the 1961 Nationality Code. The law states that any adult who acquires another nationality automatically forfeits Ivorian citizenship. Thiam is exploring ways in which to mount an appeal, according to Chichportich.
He is the fourth major political figure in Côte d'Ivoire barred from running for president, after former President Laurent Gbagbo, former Prime Minister Guillaume Soro, and former Youth Minister Charles Blé Goudé.
Côte d'Ivoire has wrestled with bouts of insecurity since the country descended into a bloody civil war in 2002 that lasted five years. Ouattara, who took office in 2011 after months of violence that followed his predecessor's refusal to accept electoral defeat, has presided over a period of economic growth that has outstripped other countries in the region.
But Ouattara's controversial decision to seek a third term — a move many opposition parties viewed as unconstitutional — triggered unrest in 2020.
'Until now, the consensus was that this election cycle would be calmer than in 2020, which saw violence,' said Chaudhuri. 'But even without unrest, uncertainty over how the vote will be conducted can impact consumption and investment — as seen in Senegal, where growth slowed and consumption fell during the 2024 election period.'
A broader concern lies beyond Thiam's case: The sudden enforcement of dormant legal provisions. The particular clause invoked against him was almost never used against political figures — except for a case in 2011 — and its reactivation raises questions about what other long-overlooked laws could be resurrected for political (or business) ends.
The Abidjan court ruled in April that Thiam lost his Ivorian citizenship in 1987 when he became French, only regaining it in March 2025 after he renounced that nationality — too late to qualify for the late 2024 electoral roll update.
Chichportich, Thiam's lawyer, argues that his client's dual nationality was long known and never contested, even during his tenure as a minister in the 1990s. Thiam has also pointed out that half of the country's football team holds dual citizenship — and that ignoring such realities would undermine the legitimacy of many public figures and national symbols.
Questions of nationality — or — have been used to sideline political opponents in Côte d'Ivoire for more than a generation. Former President Henri Konan Bédié was accused of having a Ghanaian father. Thiam's case shows how arcane legal precedents could be used to great effect to undermine high-profile individuals.
Some, including within Thiam's party, argue that he should have anticipated the legal outcome and renounced his French citizenship after being elected PDCI president in December 2023.
One adviser to French companies in Abidjan, speaking on condition of anonymity, told Semafor: 'Investors like predictability. If the Thiam decision doesn't cause turbulence, the economy keeps growing, and the country stays on a steady course, no one will make a fuss — aside from the standard formal statements from Western embassies. Everyone has their role.'
'Among many business leaders, especially SME [small and medium enterprise] heads who lived through the 2010 crisis, there's real fear and apprehension,' said Georges Yao Yao, co-founder of Y3 Audit & Conseils. 'But there's also a shared sense that, given all the progress and investment since 2011, there are strong incentives not to risk sliding backwards.'
The 'Thiam saga' shows how identity politics can still weigh heavily in Côte d'Ivoire, wrote Chatham House consulting fellow Paul Melly in a BBC article.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

European stocks poised to move lower as trade tensions and U.S. economy remain in focus
European stocks poised to move lower as trade tensions and U.S. economy remain in focus

CNBC

time2 hours ago

  • CNBC

European stocks poised to move lower as trade tensions and U.S. economy remain in focus

Good morning from London. European stocks look set to turn lower in the last trading session of the week, as investors around the world await more key data for clues on the shape of the U.S. economy. FTSE 100 futures are currently 0.1% lower, while futures tied to the French CAC 40 and Germany's DAX are down by 0.4% and 0.1%, respectively. Regional stocks ended Thursday's session higher after the European Central Bank trimmed interest rates in a widely anticipated move. U.S. nonfarm payrolls data is due to be published later on Friday, with economists expecting a contraction in jobs from the previous month. Trade tensions are also still in focus for global investors after U.S. President Donald Trump spoke with his Chinese counterpart Xi Jinping on Thursday. Trump said the 90-minute call was "very good" and "almost entirely" focused on trade. — Chloe Taylor Overnight in Asia, stocks have been trading in mixed territory as investors digest the news that Trump and Xi held what the U.S. President described as a "very good" call. On Wall Street, U.S. stock futures are trading higher ahead of May's nonfarm payrolls data. — Chloe Taylor

Sanofi (SNY) Takes Bold $9.5Bn Immunology Leap
Sanofi (SNY) Takes Bold $9.5Bn Immunology Leap

Business Insider

time3 hours ago

  • Business Insider

Sanofi (SNY) Takes Bold $9.5Bn Immunology Leap

Sanofi (SNY) has its hands full—in the best way possible—after announcing its $9.5 billion acquisition of Blueprint Medicines. This marks the French pharma giant's fourth major strategic acquisition this year, but this deal stands out. Sanofi isn't just picking up a drug or two; it's gaining access to a robust immunology pipeline of internally developed therapies. In addition to securing Ayvakit, a treatment for systemic mastocytosis, the acquisition reinforces Sanofi's shift toward high-value biopharma assets. Despite recent stock underperformance, this bold move strengthens my long-term bullish outlook on Sanofi. Confident Investing Starts Here: Sanofi's Strategic Pivot Towards High-Value Biopharma Sanofi's recent sale of Opella, its consumer healthcare division, highlights a broader strategic shift toward prioritizing high-margin biopharma operations. The company has seen major success with Dupixent—a blockbuster drug for inflammatory conditions like COPD and dermatitis, which generated over $13 billion in sales last year and now makes up nearly 30% of Sanofi's total revenue. This move underscores Sanofi's commitment to doubling down on its most profitable and innovative drug assets. Immediate Ayvakit Revenue Sanofi's acquisition of Blueprint, while a sizable investment, brings immediate benefits in both revenue diversification and pipeline strength. Ayvakit, approved for treating advanced systemic mastocytosis (AdvSM) in 2021 and indolent systemic mastocytosis (ISM) in 2023, addresses a rare disease with few treatment options. The drug generated $479 million in 2024, and Blueprint projected up to $720 million in revenue for 2025. With peak annual sales expected to reach around $2 billion before 2030, Ayvakit offers Sanofi a strong, near-term revenue driver, helping to de-risk the $9.1 billion upfront cost. Strategically, it's also a seamless addition to Sanofi's growing immunology portfolio. Boosting Sanofi's Immunology Future with Blueprint's Pipeline While Blueprint's pipeline includes several candidates, the spotlight is on two key assets: elenestinib and BLU-808. Elenestinib is a next-generation KIT D816V inhibitor currently in late-stage development for systemic mastocytosis (SM). It aims to improve upon the safety profile of Ayvakit, potentially appealing to patients who may avoid Ayvakit due to side effects such as fatigue and cognitive impairment, thereby expanding Sanofi's market share in SM. BLU-808, on the other hand, is an early-stage asset targeting a broader range of inflammatory conditions, including allergic asthma and allergic rhinoconjunctivitis. Unlike SM, these are far more prevalent diseases, offering significantly larger commercial opportunities. Importantly, BLU-808 is tied to two contingent value rights (CVRs), which are dependent on achieving specific development and regulatory milestones. These CVRs provide a layer of downside protection for Sanofi—if BLU-808 fails in clinical trials, the company's overall payout for the asset is reduced. Navigating Margin Pressures with Strategic Investment All of this comes against the backdrop of ongoing margin pressures for Sanofi. The company has already walked back its 2025 operating margin target of 32%, citing pricing pressures in its legacy general medicines segment and a ramp-up in R&D spending. While Sanofi remains active in diabetes with drugs like Lantus and Toujeo, these products now face significant pricing headwinds from generics, making them far less profitable than they once were. The Blueprint acquisition underscores Sanofi's renewed focus on innovation and high-margin biopharma assets. Though this pivot comes at the cost of near-term margin dilution, it reflects a longer-term strategy: investing in R&D today in hopes of developing the next wave of blockbuster therapies. In this context, Sanofi is clearly still in the midst of a strategic transformation—one currently anchored by the strong performance of Dupixent. Unlike previous 'bolt-on' deals that added just a drug or two, the Blueprint acquisition marks a more decisive step toward reshaping Sanofi's portfolio around premium, next-generation therapeutics. What is the Price Prediction for SNY Stock? On Wall Street, SNY sports a consensus Moderate Buy rating based on two Buy, three Hold, and zero Sell ratings in the past three months. Sanofi's average stock price target of $62.20 implies ~25% upside potential over the next 12 months. Last week, analyst Sachin Jain from Bank of America Securities maintained a Buy rating on SNY. The analyst was bullish on Sanofi's pipeline, particularly itepekimab, despite it failing in one of two Phase 3 trials for COPD. Moreover, he noted that 'Sanofi's low price-to-earnings ratio, reflecting limited pipeline upside, is seen as an opportunity given the promising data from these trials, indicating a potential R&D turnaround for the company.' Blueprint Deal Seals the Verdict on SNY In summary, Sanofi's acquisition of Blueprint offers both near-term revenue and long-term growth potential. Ayvakit serves as a valuable bolt-on asset, while pipeline candidates like elenestinib and BLU-808 significantly enhance Sanofi's immunology portfolio. More importantly, the deal reflects Sanofi's strategic pivot toward higher-margin biopharma assets at a time when older drugs like Lantus are facing profitability headwinds. Though the investment may pressure margins in the short run, it sets the stage for long-term growth in a high-value segment of the pharmaceutical market. Notably, the deal is expected to be EPS accretive by 2027, thanks to Ayvakit's revenue potential, which will help justify and offset a large portion of the upfront $9.5 billion cost. Overall, Sanofi has secured a promising set of assets at a reasonable valuation while extending its leadership in immunology beyond Dupixent. With a modest P/E ratio of 20.5 and a solid 3.27% dividend yield, SNY stands out as a compelling long-term investment opportunity for investors seeking to tap into the expanding biopharmaceutical space.

Marc Garneau died after 'short but very difficult battle' with cancer, former staffer says
Marc Garneau died after 'short but very difficult battle' with cancer, former staffer says

Yahoo

time3 hours ago

  • Yahoo

Marc Garneau died after 'short but very difficult battle' with cancer, former staffer says

Marc Garneau died this week after being diagnosed with two types of cancer earlier this year, his former staffer says. The first Canadian to travel to space and former cabinet minister died on Wednesday. He was 76. Marc Roy, Garneau's former chief of staff, told CBC's Power & Politicsthat the former minister had been diagnosed with lymphoma and leukemia earlier this year. "He fought a short but very difficult battle with two very rare types of cancer," Roy told host David Cochrane. "Although his diagnosis was only a couple of months ago, he was well until four or five weeks ago. So it went very, very quickly … it's a very, very tough loss." Roy said Garneau only shared his diagnosis with a small circle that agreed to respect his wish for privacy. "[It was] something he wanted to keep with his family so he could concentrate on his time with his family and not distract his family by the attention it could have gotten," Roy said. WATCH | It's a tragic loss,' says former chief of staff: Beyond his legacy as an astronaut, Garneau held a number of federal cabinet positions since 2015, including in transport and foreign affairs. Roy said Garneau was "tremendous" to work for as he reflected on his time in politics. "It's a huge loss to government. I think that his years in Ottawa are filled with many contributions to improving safety and expanding policy. I think he will be remembered for that for decades to come," Roy said. The House of Commons held another moment of silence for Garneau on Thursday and MPs took time to pay tribute to their former colleague. "He reminded us that Canadians can dream big, that we could aim for the stars quite literally," Government House leader Steve MacKinnon said. "He became a powerful symbol of the achievement and the accomplishment of this great country of ours." Like MacKinnon, other MPs reflected on how Garneau inspired Canadians. "Mr. Garneau, the future will always be inspired by your life, which was so inspiring for all Canadians," Conservative MP Gérard Deltell said in French. WATCH | Garneau's 'extraordinary ride': Bloc Québécois MP Rhéal Fortin said Garneau paved the way for other Canadians to journey to space, including Chris Hadfield and Julie Payette. "He showed us the way to the stars," Fortin said in French. Fighting back tears, Green Party Leader Elizabeth May said it was hard to say goodbye to "someone who was unfailingly kind [and] unfailingly respectful." "We've lost a very great human being, and to his entire family: my deepest condolences and sympathy — and know that in that space where he looks down at planet Earth now, I think it's a place called heaven."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store